In Brief
This article was originally published in The Tan Sheet
Executive Summary
Watson adds Actavis for $5.6 bil.; Recordati buys OTCs in Germany; DoJ weighs in on Plan B case; NARC rebranded as ASRC; Korean lawmakers miss another chance on OTC bill; more news In Brief.
You may also be interested in...
Actavis Realigns OTC, Rx Businesses To Increase Efficiency
The global specialty brand and generics company is simplifying its structure and combining units to make communication and decisions across the business more effective as it strives to grow organically.
Actavis Realigns OTC, Rx Businesses To Increase Efficiency
The global specialty brand and generics company is simplifying its structure and combining units to make communication and decisions across the business more effective as it strives to grow organically.
Actavis’ Warner Chilcott Buy Brings Switch Options In Diversified Portfolio
Actavis’ acquisition of Warner Chilcott creates a women’s health powerhouse with Rx-to-OTC switch potential. UBS analysts expect $400 million in cost synergies and an “even more robust than previously disclosed” pipeline and diverse product portfolio that complements Actavis’ existing products.